CNS Pharmaceuticals Inc.

12/02/2021 | Press release | Distributed by Public on 12/02/2021 07:42

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)